Sex-specific effects of metformin and liraglutide on renal pathology and expression of connexin 45 and pannexin 1 following long-term high-fat high-sugar diet by Luetić, Martina et al.
Acta Histochemica 123 (2021) 151817
Available online 19 November 2021
Research paper 
Sex-specific effects of metformin and liraglutide on renal pathology and 
expression of connexin 45 and pannexin 1 following long-term high-fat 
high-sugar diet 
Martina Luetić a, Genia Kretzschmar b, Maximilian Grobe b, Leo Jerčić b, Ivana Bota b, 
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Robert Gaspar d, Tamas Tabi e, Katarina Vukojević b,f, Sandor G. Vari g, Natalija Filipović b,* 
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b University of Split School of Medicine, Laboratory for Neurocardiology, Department of Anatomy, Histology and Embryology, Šoltanska 2, Split 21000, Croatia 
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A B S T R A C T   
The comparative effects of the two commonly used antidiabetic drugs metformin and liraglutide on renal pa-
thology and expression of connexin 45 (Cx45) and pannexin 1 (Panx1) in adult obese rats fed high-fat high-sugar 
diet (HFHSD) were studied. Considering recent data on the profound influence of sex on metformin and lir-
aglutide effects, we compared the effects of both drugs between male and female animals. 44-week-old Sprague- 
Dawley rats were separated into 4 groups that were fed: standard diet, HFHSD, HFHSD treated with metformin 
(s.c., 50 mg/kg/day) and HFHSD treated with liraglutide (s.c., 0.3 mg/kg/day). Treatment with metformin or 
liraglutide lasted for 14 weeks. Histology and immunohistochemistry were performed to quantify renal patho-
logical changes and Cx45 and Panx1 expression. HFHSD caused thickening of the Bowman’s capsule (BC). Both 
metformin and liraglutide failed to ameliorate the BC thickening; metformin even worsened it. Effects on the 
tubulointerstitial fibrosis score, BC thickness and Cx45 and Panx1 expression were sex-dependent. We found a 
50% increase in mitochondria in proximal tubules of metformin- and liraglutide-treated HFHSD-fed rats, but 
these effects were not dependent on the sex. This is a first study showing that the effects of metformin and 
liraglutide on kidney pathology in rats fed HFHSD are mostly sex-dependent and that these effects are not 
necessarily beneficial. Both drugs changed the Cx45 and Panx 1 expression; hence their effects could be related to 
amelioration of disruptions in intercellular communication.   
1. Introduction 
Metabolic syndrome (MS) consists of different abnormalities 
including insulin resistance, dyslipidaemia, hypertension and obesity, 
which have a great impact on the development of cardiovascular disease 
(Eckel et al., 2005; Prasad, 2014; Zhang and Lerman, 2017). Although 
these single components of MS are associated with chronic kidney dis-
ease (CKD), the prevalence and progression of CKD is also affected 
directly and independently by MS (Prasad, 2014; Nashar and Egan, 
2014). All mechanisms involved in the pathophysiology of MS such as 
oxidative stress, inflammation, insulin resistance, endothelial dysfunc-
tion and increased expression of pro-fibrotic factors play an important 
role in the pathogenesis of renal damage in CKD (Singh and Kari, 2013; 
Prasad, 2014). In histopathological examination of damaged kidneys 
from patients with MS, tubular atrophy, interstitial fibrosis, global and 
segmental glomerulosclerosis can be observed (Alexander et al., 2009). 
Kidney damage related to MS resembles the early stage of diabetic ne-
phropathy (DN) characterized by the thickening of the glomerular 
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basement membrane (GBM) (Tervaert et al., 2010; Zhang and Lerman, 
2016), and probably includes Bowman’s capsule (BC) thickening as well 
(Holderied et al., 2015). 
Regardless of the CKD initiator, pathological process ultimately leads 
to the disruption of gap junction intercellular communication, affecting 
the expression levels of connexin (Cx) proteins that form the commu-
nication channels (Toubas et al., 2011). Six identical or different Cx 
isoforms compose a structure called connexon, each localised on the cell 
membrane, which is interconnected to the connexon of the neighbouring 
cell allowing the passage of ions, nutrients and small signalling mole-
cules (Haefliger et al., 2001; Toubas et al., 2011). There are more than 
20 Cx family members known today and 9 of them have been detected in 
different parts of kidney, at least at the mRNA level. In rodents, location, 
expression and function of renal Cx37, Cx40, Cx43 and Cx45 have been 
studied the most (Hanner et al., 2010; Haefliger et al., 2001). So far, the 
expression of Cx45 has been found in renal vascular smooth muscle cells 
of afferent and efferent arterioles, intraglomerular and extraglomerular 
mesangial cells, renin producing juxtaglomerular cells, podocytes and 
distal tubules (Hanner et al., 2008, 2010). Nevertheless, in our previous 
work (Saric et al., 2017; Luetić et al., 2020), we found that Cx45 is the 
most prominent Cx expressed in proximal tubules of the rat kidney and 
its expression is substantially decreased in streptozotocin-induced dia-
betes mellitus (DM) type 1. However, there are still insufficient data 
about the exact role of Cx45 and the findings of its distribution in the 
kidneys are conflicting (Hanner et al., 2010). 
In contrast to connexins, members of the pannexin family (Panx1, 
Panx2 and Panx3) (Willebrords et al., 2017) of Cx-resembling proteins 
do not form gap junctions, although they assemble hexameric mem-
brane channels (Adamson et al., 2015; Willebrords et al., 2017). Panx1 is 
widely expressed in different tissues and cells including endothelium of 
renal vasculature and renal tubules (Abed et al., 2015; Chiu et al., 2018). 
Although the role of Panx1 in the kidneys is still unknown, some data 
suggest a role of Panx1 in controlling blood pressure. Panx1 is related to 
DM and insulin resistance also (Adamson et al., 2015; Cui et al., 2016; 
Chiu et al., 2018; Luetić et al., 2020). 
Insulin resistance is considered to be the most important factor in MS 
for development of CKD (Prasad, 2014). Therefore, metformin, which 
improves insulin sensitivity, is potentially a very good option for 
reducing renal damage related to MS (Nashar and Egan, 2014; Felice 
et al., 2017). It was demonstrated that administration of metformin in 
mice with MS reduces mesangial matrix expansion and micro-
albuminuria (Kim et al., 2013). Renoprotective effects of metformin 
were observed in various animal and in vitro models of kidney disease, 
comprising a reduction in GBM thickness and the attenuation of tubu-
lointerstitial fibrosis (Zhang et al., 2017a, 2017b; de Broe et al., 2018). 
Nevertheless, the use of metformin in patients with CKD is limited by the 
value of the estimated glomerular filtration rate (eGFR) to prevent the 
risk of lactic acidosis development (Lazarus et al., 2018). Liraglutide, a 
glucagon-like peptide-1 (GLP-1) receptor agonist is suggested as a novel 
therapeutic agent for the treatment of MS considering its potential to 
reduce insulin resistance (Lim and Eckel, 2014). Protective renal effects 
of liraglutide in MS including reduced glomerulosclerosis and interstitial 
fibrosis are observed in obese rats fed a high-fat diet (HFD) (Wang et al., 
2018). Likewise, attenuation of renal fibrosis is demonstrated after lir-
aglutide treatment in a rat DM2 model (Chen et al., 2018) and mice with 
unilateral ureteral obstruction (UUO) (Li et al., 2018). 
Observations about the influence of metformin and liraglutide on Cx 
expression and function come from studies of the cardiovascular system 
where both of the drugs upregulated Cx43 expression and thus improved 
cardiac function (Noyan-Ashraf Mohammad et al., 2013; Wang et al., 
2017). However, there are no data on the effects of MS and the treatment 
with metformin or liraglutide on expression of Cx proteins in the kidney. 
Our study aimed to investigate the comparative effects of metformin 
and liraglutide treatment on renal pathology and expression of Cx45 and 
Panx1 in kidney of rats fed a high-fat high-sugar diet (HFHSD). Based on 
the previous data about beneficial effects of metformin and liraglutide 
on renal function, we hypothesized that both therapeutic options can 
attenuate the progression of CKD and lessen kidney damage. Consid-
ering recent data that show the effects of metformin and liraglutide in 
the other organs are profoundly influenced by sex, we also aimed to 
compare the effects of both drugs on male and female animals. 
2. Materials and methods 
2.1. Animals 
A total of 48, 44-week-old Sprague-Dawley rats of both sexes were 
used in this study. All procedures were approved by the Hungarian 
Ethical Committee for Animal Research (registration number IV/3796/ 
2015). Rats were maintained under controlled laboratory conditions at 
the Animal Facility, University of Szeged in Szeged, Hungary. 
2.2. Experimental procedure 
Animals were randomly separated into four groups: control rats (C; n 
= 5 for female and n = 6 for male group), untreated rats fed high-fat 
high-sugar diet (HFHSD; C 1011 Carbohydrate & fat-rich diet, Altro-
min Spezialfutter GmbH & Co. Lage, Germany; see Supplementary 
Table 1; n = 5 female and N = 5 male animals), metformin-treated rats 
fed HFHSD (HFHSD+Metf.; n = 6 female, n = 8 male rats) and 
liraglutide-treated rats fed HFHSD (HFHSD+Lir.; n = 5 female, n = 8 
male rats). The control group was fed standard chow. Control diet 
(Altromin 1324) contained 65% carbohydrate (5% disaccharide, 39% 
polysaccharide), 11% fat and 24% protein. HFHS diet (Altromin C1011) 
contained 56% carbohydrate (18% disaccharide, 36% polysaccharide), 
28% fat and 16% protein. Six weeks after the beginning of HFHSD, 
animals from the HFHSD+Metf. group received 50 mg/kg/day of met-
formin while the HFHSD+Lir. animals were given 0.3 mg/kg/day of 
liraglutide. Both drugs were administered subcutaneously for 14 weeks. 
There are several daily metformin doses for rats in the literature (from 
10 mg/kg to 500 mg/kg or even more). We carried out a chronic met-
formin treatment, therefore we applied the dosage of Narasimhan et al. 
(2015) in which the rats were treated 30 days with 50 mg/kg metformin 
daily and its antidiabetic action was investigated in vivo. The liraglutide 
dose for rat is very similar in the literature (0.1–0.4 mg/kg daily), the 
only difference is the once or twice administration in 24 h. We have 
chosen a single daily 0.3 mg/kg daily dose based on the research of 
Geddawy et al. (2017) in which metabolic syndrome rats were treated 
the same way for 6 weeks. Intraperitoneal glucose tolerance test (IPGTT) 
was made at week 18. Each rat was treated intraperitoneally with 
glucose solution (25%) injecting 2 mg/kg dose. Blood glucose levels 
were determined prior and 2 h after the injection. Blood samples were 
obtained from tail vein using glucometer (OneTouch UltraMini, Milpi-
tas, USA). After the animals were sacrificed, at Week 19 in deep iso-
flurane (Forane; Baxter Healthcare Corp. Deerfield, USA) anesthesia by 
cardiac puncture and collection of whole blood content the prepared 
serum samples were stored at − 20 ◦C for further measurements. The 
kidneys were removed, quickly cleaned from fat and immediately 
measured by an analytical scale (ENTRIS64-1S, Sartorius AG, Goettin-
gen, Germany). After the weight measurements, the kidneys were fixed 
in buffered 4% paraformaldehyde for further analyses. 
2.3. Blood biochemistry 
Triacylglycerols (TAG) were determined from serum samples ob-
tained in the fasting state, by standard clinical laboratory methods in the 
Central Clinical Laboratory of Semmelweis University. 
2.4. Histology and immunohistochemistry 
Tissues were washed in phosphate buffer (PBS, pH 7.2), dehydrated 
and embedded in paraffin wax (Vitlov Uljevic et al., 2018, 2019). Five 
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µm thick sections were made. After deparaffinization and rehydration, 
sections were heated at 95 ◦C for 12 min in citrate buffer (pH 6.0) and 
washed with PBS. Incubation with primary antibodies (Table 1) was 
performed overnight following standard immunohistochemical pro-
cedures (Vitlov Uljevic et al., 2018; Luetić et al., 2020). Appropriate 
secondary antibodies (Table 1) were applied for 1 h. The slides were 
then air-dried and coverslipped (Immu-Mount, Shandon, Pittsburgh, PA, 
USA). 
Alternatively, after deparaffinization, kidney sections were stained 
by phosphotungstic acid hematoxylin (PTAH), periodic acid Schiff 
(PAS), or Mallory’s trichrome staining. 
2.5. Data acquisition and analyses 
Sections were viewed and analysed by a blinded pathologist using a 
microscope (BX61, Olympus, Tokyo, Japan) equipped with a cooled 
digital camera (DP71, Olympus, Tokyo, Japan). For further analyses, 
ImageJ software (National Institutes of Health, Bethesda, MD, USA) was 
used. 
In each section expression of Cx45 was determined in 7–8 visual 
fields of kidney cortex captured at 400 × magnification and constant 
exposure time. A red granular pattern was interpreted as immunoreac-
tive for Cx45 positivity. The percentage of immunoreactive area in the 
total examined area was calculated. 
Expression of Panx1 was analysed in glomeruli and tubules using 10 
randomly selected cortical areas of the kidney per animal (photographed 
at 400 × magnification). Green granular deposits were interpreted as 
positive for Panx1. Quantification was made by counting deposits in 
glomeruli and tubules separately. 
For PAS analyses, 20 non-overlapping areas of kidney cortex with at 
least one glomeruli included per section were photographed at a 
magnification of 400 × . 
BC thickness was also analysed in 20 glomeruli. Thickness of the BC 
was measured from at least six different points which were randomly 
selected using a grid tool with random offset in ImageJ; the exact points 
of measurement were intersections of vertical and horizontal lines with 
the outer membrane of BC. 
From the obtained images of kidney cortex, 20 glomeruli were 
randomly examined in which glomerular damage was estimated and 
graded as 0 – normal, 1 – minimal sclerosis (<25%), 2 – mild sclerosis 
(25–50%), 3 – moderate sclerosis (50–75%), 4 – severe sclerosis 
(>75%). The glomerular score for each animal was determined using the 
formula: (0 × x0) + (1 × n1) + (2 × n2) + (3 × n3) + (4 × n4) / n0 + n1 +
n2 + n3 + n4. Element nx represents the number of equally graded 
glomeruli (Maric et al., 2004; Yabuki et al., 2006). 
The estimation of tubulointerstitial fibrosis was made using the 
photomicrographs of the entire cortical area of each kidney section 
stained by Mallory’s trichrome staining which were obtained under 100 
×magnification. Tubulointerstitial fibrosis was graded as 0 – normal, 1 – 
less than 10%, 2 – 10–25%, 3 – 25–75%, 4 – more than 75% fibrosis 
(Yabuki et al., 2006; Glastras et al., 2016). 
For analysis of mitochondria, 17–21 visual fields of PTAH-stained 
sections captured at 400 × magnification were analysed, to quantify 
the mitochondria covered % area of the section. 
2.6. Statistical analyses 
For calculation of the sample size we used the Mead’s resource 
equation (Mead et al., 2012; Arifin, 2017), for the case of one-way group 
(between-subject) comparison. Accordingly, the calculated minimal size 
of the experimental group should be n= 4. PAST 3.22 Software was used 
for statistical analyses (Hammer et al., 2001). In order to compare data 
between experimental groups Kruskal-Wallis test, followed by the 
Mann-Whitney test was used. Statistical significance was set at p < 0.05. 
3. Results 
3.1. Kidney weights and biochemical parameters 
Kidney weights and biochemical parameters are presented in a  
Table 2. We observed slightly higher total kidney weights in female 
HFHSD+Lir. (absolutely and relatively to the body mass), but these 
difference s were not significant (p = 0.0345 in comparison to C, but 
Kruskal-Wallis test was p = 0.0874). In opposite, we noticed signifi-
cantly lower total kidney weight in male HFHSD+Lir. rats (p = 0.0239 
compared to Ctrl. and p = 0.0181 in comparison to HFHSD). However, 
there was no significant difference in renal mass of male rats, when 
expressed as % of body weight. We observed disturbed blood glucose 
control in all female animals (including the Ctrl. group), that were not 
able to restore glycaemia two hours after receiving intraperitoneally 2 
Table 1 
Primary and secondary antibodies.   
Antibody Code No. Host Dilution Source 
Primary Anti-Connexin 45/GJA7/Cx45 antibody sc-135474 Rabbit 1:100 Abcam plc. 330 Cambridge, CB4 OFL, UK 
Anti-Pannexin-1/PANX1 Antibody ABN242 Rabbit 1:100 Merck KGaA, Darmstadt, Germany 
Secondary AlexaFluor®488 Affini Pure Donkey Anti-Rabbit IgG (H+L) 711–545–152 Donkey 1:400 Jackson Immuno Research Laboratories, Inc., Baltimore, 




Kidney weights and biochemical parameters.    
Parameter Mean±SD (unit) 
Total kidney weight 
(g) 
Total kidney weight (% of body 
weight) 
2 hr blood glucose (mg/ 
dL) 




Female Ctrl. 2,04 ± 0,20 0,55 ± 0,03 242,75 ± 128,24 342,33 ± 147,35 0,90 ± 0,25 
HFHSD 2,33 ± 0,65 0,52 ± 0,08 419,80 ± 134,93 622,03 ± 232,68 1,48 ± 0,75 
HFHSD+Metf. 2,33 ± 0,28 0,56 ± 0,05 291,67 ± 103,84 408,79 ± 153,02 1,21 ± 0,48 
HFHSD+Lir. 2,42 ± 0,19 0,69 ± 0,10 366,20 ± 133,64 479,50 ± 226,60 0,68 ± 0,33#$ 
Female - p  0,1434 0,0874 0,2809 0,1364 0,0454 
Male Ctrl. 3,96 ± 0,39 0,66 ± 0,07 98,00 ± 3,56 146,37 ± 5,30 0,52 ± 0,08 
HFHSD 3,62 ± 0,22 0,55 ± 0,07 195,00 ± 97,86 * 247,43 ± 106,23 * 0,91 ± 0,24 * 
HFHSD+Metf. 3,82 ± 0,37 0,58 ± 0,07 192,83 ± 59,90 * 289,90 ± 88,57 * 1,00 ± 0,34 * 
HFHSD+Lir. 3,49 ± 0,57 * $ 0,58 ± 0,07 223,25 ± 107,66 * 276,58 ± 106,94 * 0,73 ± 0,26 
Male – p  0,0335 0,1336 0,0209 0,0171 0,0059 
Kruskal-Wallis test followed by Man-Whitney test. p ≤ 0.05 compared to: * Ctrl.; # HFHSD; $ HFHSD+Metf. 
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mg/kg glucose. However, rats in Ctrl. female group had 342.33 ±
147.35% of initial glucose values 2 hr after the glucose injection, while 
rats in untreated HFHSD female group had 622.03 ± 232.68% of initial 
glucose value and these values were slightly lower in HFHSD+Metf. and 
HFHSD+Lir. groups, but these differences were not significantly 
different. In opposite to female, male rats in Ctrl. group were able to 
effectively restore glycaemia (146.37 ± 5.30% of initial blood glucose 
value 2 hr after intraperitoneal glucose injection). However, HFHSD in 
male rats resulted in increased 2hr-blood glucose value (p = 0.0518 
compared to the Ctrl.), which was not restored by metformin or lir-
aglutide treatment (Ctrl. vs. HFHSD+Metf. p = 0.0142; Ctrl. vs. 
HFHSD+Lir. p = 0.0085). In addition, we observed an increase in serum 
triacylglycerols in female HFHSD and HFHSD+Metf. Groups, but these 
differences did not reach significant value. However, in HFHSD+Lir. 
group we found significantly lower values of serum triacylglycerols, 
when compared to HFHSD (p = 0.0481) of HFHSD+Metf. group (p =
0.0348). In agreement with that, in male HFHSD and HFHSD+Metf. 
groups, serum triacylglycerol values were significantly higher in com-
parison to Ctrl. group (p = 0.0439 and p = 0.0053; respectively); while 
serum triacylglycerols were not increased in rats from HFHSD+Lir. 
group. 
Fig. 1. Periodic acid Schiff (PAS) staining of 
kidney sections. Representative photomicro-
graphs of renal sections stained with PAS. 
Objective magnification: 40 × . BC, Bowman’s 
capsule; arrowheads indicate thickening of the 
BC; Ctrl., control group; HFHSD, untreated 
high-fat high-sugar diet fed group; 
HFHSD+Metf., metformin-treated HFHSD fed 
group; HFHSD+Lir., liraglutide-treated HFHSD 
fed group; F, female; M, male. # - p < 0.05, ## 
- p < 0.01 significant difference between indi-
cated female groups; * - p < 0.05, ** - p < 0.01, 
*** - p < 0.001 significant difference between 
indicated male groups (Kruskal-Wallis ANOVA, 
followed by the Mann-Whitney test). Graphs 
show Mean±SD. Scale-bar = 20 µm.   
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3.2. The influence of metformin and liraglutide therapy on Bowman’s 
capsule thickness 
HFHSD significantly increased the thickness of the BC in female (Ctrl. 
vs. HFHSD p = 0.0122; Ctrl. vs. HFHSD+Metf. p = 0.0081; Ctrl. vs. 
HFHSD+Lir. p = 0.0122) and male rats (Ctrl. vs. HFHSD p = 0.0081; 
Ctrl. vs. HFHSD+Metf. p = 0.0024; Ctrl. vs. HFHSD+Lir. p = 0.0024;  
Fig. 1). In females, both metformin and liraglutide failed to demonstrate 
any significant effect on the thickness of BC in HFHSD fed rats. In males, 
however, HFHSD fed rats treated with metformin had the thickest BC, 
and the thickness was significantly greater when compared to the BC of 
the animals from all-male HFHSD groups (p = 0.0104 vs. HFHSD and p 
= 0.0009 vs. HFHSD+Lir.). 
3.3. Metabolic syndrome-related glomerulosclerosis 
We did not observe significant differences between groups in the PAS 
glomerular score, except a significant decrease in liraglutide-treated 
females in comparison to all other female groups (p = 0.0157 vs. Ctrl.; 
p = 0.0119 vs. HFHSD and p = 0.0080 vs. HFHSD+Metf.; Figure1). 
3.4. Drug-associated alteration of tubulointerstitial fibrosis 
HFHSD resulted in tubulointerstitial fibrosis in rats of both, male 
(Ctrl. vs. HFHSD p = 0.0081) and female rats (Ctrl. vs. HFHSD 
p = 0.0119; Fig. 2). Administration of metformin markedly increased 
the degree of fibrosis (Ctrl. vs. HFHSD+Metf. in male p = 0.0024 and in 
female p = 0.0074) and in female rats it even aggravated fibrotic 
changes compared to the female HFHSD group (p = 0.0075). Never-
theless, liraglutide significantly reduced tubulointerstitial fibrosis in 
HFHSD fed male rats (p = 0.0063 vs. HFHSD and p = 0.0009 vs. 
HFHSD+Metf.). 
3.5. PTAH staining - drug-associated alteration of mitochondria 
HFHSD did not cause significant changes in the mitochondria % area 
(Fig. 3). On the other hand, administration of either metformin to the 
HFHSD fed animals significantly increased the mitochondria % area in 
both, female (p = 0.0081 vs. Ctrl. and p = 0.0081 vs. HFHSD) and male 
rats (p = 0.0104 vs. HFHSD). The same effect was also found for the 
liraglutide: in female (p = 0.0122 vs. Ctrl. and p = 0.0122 vs. HFHSD), 
as well as in male animals (p = 0.0168 vs. Ctrl. and p = 0.0043 vs. 
HFHSD). These effects obviously were not dependent on the sex of the 
animals. 
3.6. Expression of Cx45 and Panx1 in the rat kidneys 
We observed the dominant Cx45 expression in proximal tubules with 
a relatively low level of expression in glomeruli (Fig. 4). This was in 
agreement with results of our previous study (Luetić et al., 2020), in 
Fig. 2. Drug associated alteration of tubu-
lointerstitial fibrosis. Representative photomi-
crographs of renal sections stained by Mallory’s 
trichrome staining. Objective magnification: 
40 × . T/I, tubulointerstitial; arrowheads indi-
cate T/I fibrosis; Ctrl., control group; HFHSD, 
untreated high-fat high-sugar diet fed group; 
HFHSD+Metf., metformin-treated HFHSD fed 
group; HFHSD+Lir., liraglutide-treated HFHSD 
fed group; F, female; M, male. # - p < 0.05, ## 
- p < 0.01- significant difference between indi-
cated female groups; * * - p < 0.01, *** - 
p < 0.001 significant difference between indi-
cated male groups (Kruskal-Wallis ANOVA, 
followed by the Mann-Whitney test). Graphs 
show Mean±SD. Scale-bar = 20 µm.   
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which proved the prevailing presence of the Cx45 in the proximal tu-
bules, on a base of PTC morphology and the co-localization with the 
DBA, a Dolichos biflorus agglutinin. In female animals, liraglutide upre-
gulated Cx45 expression in comparison with the control and HFHSD 
groups (p = 0.0122 and p = 0.0216, respectively). In male rats, 
expression of Cx45 in the HFHSD+Metf. group was markedly increased 
compared to the control group (p = 0.0239). However, there was no 
difference in Cx45 expression between rats from the HFHSD and control 
groups. Expression of Cx45 was significantly higher in HFHSD+Lir. male 
group, when compared to control (p = 0.0168) and HFHSD group 
(p = 0.0103). 
The pannexin dots appeared mostly in glomeruli. In case that they 
were found outside the glomeruli, their appearance was located in the 
tubuli, mostly in DCT. This finding was in agreement with our previous 
study on diabetic rats (Luetić et al., 2020). Panx1 immunoreactive 
puncta were only rarely found in the interstitium or in the endothelium 
of the vessels. In glomeruli, expression of Panx1 was significantly higher 
in male rats treated with metformin in comparison to the control group 
(p = 0.0188; Fig. 5). In females, expression of Panx1 in glomeruli was 
the highest in HFHSD+Lir. group (p = 0.0114 vs. Ctrl.; p = 0.0204 vs. 
HFHSD and p = 0.0077 vs. HFHSD+Metf.). In tubules, Panx1 was 
upregulated in the female group on metformin therapy (p = 0.0080 vs. 
Ctrl. and p = 0.0081vs. HFHSD+Lir.). Tubulo/interstitial expression of 
Panx1 in male rats was increased in all groups fed HFHSD when 
compared to control animals (Ctrl. vs. HFHSD p = 0.0358; Ctrl. vs. 
HFHSD+Metf. p = 0.0081 and Ctrl. Vs. HFHSD+Lir. p = 0.0280). 
4. Discussion 
In this study, we investigated the comparative effects of metformin 
and liraglutide treatment on renal pathology and expression of Cx45 and 
Panx1 in the kidneys of Sprague-Dawley HFHSD-fed rats and compared 
the effects of both drugs between male and female animals. We found 
disturbed blood glucose control in all female animals (including the Ctrl. 
group), that were not able to restore glycaemia two hours after receiving 
intraperitoneally 2 mg/kg glucose. In opposite to female, male rats in 
Ctrl. group were able to effectively restore glycaemia while, HFHSD in 
resulted in increased 2hr-blood glucose value, which was not restored by 
metformin or liraglutide treatment. In addition, we found that liraglu-
tide treatment was able to decrease serum triacylglycerol values of 
HFHSD fed rats, but metformin did not. 
Glomerular damage is a feature of MS and includes mesangial matrix 
expansion, podocyte injury and glomerular fibrosis (Kim et al., 2013). In 
addition to the glomerular damage, MS also affects other parts of the 
nephron, causing tubular atrophy and interstitial fibrosis (Alexander 
et al., 2009). The most prominent pathological change that we found in 
kidneys of HFHSD-fed rats was pronounced tubulointerstitial fibrosis. In 
female rats, metformin treatment did not ameliorate tubulointerstitial 
fibrosis; rather it even worsened it. In contrast, in male animals, treat-
ment with liraglutide significantly ameliorated tubulointerstitial 
fibrosis. Our findings are concordant with those of other studies that 
showed beneficial effects of liraglutide in preventing the progression of 
tubulointerstitial fibrosis in HFD-fed rats (Wang et al., 2018), in a rat 
DM2 model (Chen et al., 2018) and in a mouse UUO model of renal 
Fig. 3. Phosphotungstic acid hematoxylin 
(PTAH) - drug associated alteration of mito-
chondria. Representative photomicrographs of 
renal sections stained by PTAH. Objective 
magnification: 40 × . Ctrl., control group; 
HFHSD, high-fat high-sugar diet fed group; 
HFHSD+Metf., metformin-treated HFHSD fed 
group; HFHSD+Lir., liraglutide-treated HFHSD 
fed group; F, female; M, male. # - p < 0.05, ## 
- p < 0.01 - significant difference between 
indicated female groups; * - p < 0.05, * * - 
p < 0.01 significant difference between indi-
cated male groups (Kruskal-Wallis ANOVA, 
followed by the Mann-Whitney test). Graphs 
show Mean±SD. Scale-bar = 20 µm.   
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fibrosis (Li et al., 2018). However, female specific whorsening of the 
tubulointerstitial fibrosis in metformin-treated rats was unexpected. 
The most prominent change that we found in glomeruli was the 
thickening of the BC, which was evident in all groups of animals fed 
HFHSD. The treatment with each of the medications did not ameliorate 
it. Moreover, metformin treatment even worsened it, specifically in male 
rats. We did not find significant changes in the glomerular PAS score 
between experimental groups, except for a significant decrease in the 
female group treated with liraglutide, even in comparison with the 
control group. This could be explained by amelioration of normal ageing 
changes in glomeruli by liraglutide. Changes in glomeruli were subtle, 
and the only visible sign of damage was BC thickening. This could be a 
reason why this type of damage might often go unnoticed and under-
estimated in pathological examination. In support, we did not observe 
substantial changes in total renal mass expressed as % of body weight 
caused by HFHSD, although we found slightly higher total kidney 
weights in female HFHSD+Lir. and lower total kidney weight in male 
HFHSD+Lir. Previous studies of obesity-induced kidney injury in rats 
have shown that liraglutide therapy has beneficial effects on fibrotic 
lesions (Wang et al., 2018). Gender-related variations of liraglutide ef-
fects could be explained by differences in drug metabolism. Since in 
males an increased rate of elimination of liraglutide was observed 
(Cataldi et al., 2019), there is a shortened period for liraglutide to 
achieve its full therapeutic potential. 
Histopathological changes in the kidneys related to MS are similar to 
the ones seen in DN due to their overlapping pathophysiological 
processes (Zhang and Lerman, 2017). In the early stage of DN, thick-
ening of the GBM is evident by electron microscopy (Tervaert et al., 
2010). It was also proven that metabolic alterations in DN lead to BC 
thickening as well (Holderied et al., 2015). Although there are still no 
data in literature about, these changes very likely occur in MS. Our re-
sults are the first to show the thickening of the BC in association with 
HFHSD. Moreover, gender-related changes in the BC thickness were 
observed concerning the therapeutic option where metformin signifi-
cantly increased the thickness of BC in male animals when compared to 
all other groups of males. 
Besides, we found an increase of approximately 50% in mitochondria 
in proximal tubules of both the metformin- and liraglutide-treated 
HFHSD fed rats. These results are in agreement with numerous studies 
that relate both metformin and liraglutide with biogenesis, function and 
reduction of oxidative stress in mitochondria of different organs (Pin-
tana et al., 2013; Sa-Nguanmoo et al., 2017; Karise et al., 2019; Pal et al., 
2019; Vial et al., 2019; Wu et al., 2019). However, we found that these 
effects were not sex-specific. 
Cx45 is far more intriguing than all other Cxs relevant to renal 
function and pathology, because its role in the kidneys is still unex-
plained and precise localisation remains unclear (Hanner et al., 2010). 
In the present study, as we had already observed (Saric et al., 2017; 
Luetić et al., 2020), the most prominent expression of Cx45 was 
observed in proximal tubules, suggesting its involvement in various 
processes which occur in this part of the nephron. Concerning a notable 
role of the proximal tubules in the development of tubulointerstitial 
Fig. 4. Expression of connexin 45 (Cx45) in the 
kidneys of experimental rats. Representative 
photomicrographs of renal sections stained by 
Cx45-immunohistochemistry. Objective magni-
fication: 40 × . Ctrl., control group; HFHSD, 
high-fat high-sugar diet fed group; 
HFHSD+Metf., metformin-treated HFHSD fed 
group; HFHSD+Lir., liraglutide-treated HFHSD 
fed group; F, female; M, male. # - p < 0.05 - 
significant difference between indicated female 
groups; * - p < 0.05 - significant difference be-
tween indicated male groups (Kruskal-Wallis 
ANOVA, followed by the Mann-Whitney test). 
Graphs show Mean±SD. Scale-bar = 20 µm.   
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fibrosis (Gewin, 2018), the changes of Cx45 expression may be related to 
the progression of the fibrotic lesions. Our results have shown that 
expression of Cx45 is gender- and drug-dependent; in male rats treated 
with metformin the level of Cx45 was the highest whereas in females 
liraglutide had the same effect. Drug-related changes in Cx expression 
were observed in previous studies on the cardiovascular system where 
both metformin and liraglutide increased the levels of Cx43 (Noya-
n-Ashraf Mohammad et al., 2013; Wang et al., 2017). These findings are 
in agreement with those from studies in cardiac cells in vitro (Wang 
et al., 2017) and mice with HFD-induced obesity associated with MS 
(Noyan-Ashraf Mohammad et al., 2013). Considering our data, 
upregulation of Cx45 could be a mechanism associated with ameliora-
tion of the tubulointerstitial fibrosis, since we did not find the increase in 
Cx45 expression in untreated HFHSD-fed animals. The sex difference 
could be due to the slower tubular elimination of liraglutide in females 
(Cataldi et al., 2019) which may lead to a prolonged effect of liraglutide 
in renal tissue. 
An increase of Cx45 tubular expression in liraglutide treated rats fed 
HFHSD could be at least partially explained by ability of liraglutide to 
restore disturbed endoplasmic reticulum (ER) homeostasis. Namely, 
HFD causes ER stress and affects folding and trafficking of proteins, 
including the connexins, with accumulation of misfolded forms which 
Fig. 5. Expression of pannexin 1 (Pnx1) in the 
kidneys of experimental rats. Representative 
photomicrographs of renal sections stained by 
Pnx1-immunohistochemistry. Objective magni-
fication: 40 × . Ctrl., control group; HFHSD, 
high-fat high-sugar diet fed group; 
HFHSD+Metf., metformin-treated HFHSD fed 
group; HFHSD+Lir., liraglutide-treated HFHSD 
fed group; F, female; M, male. # - p < 0.05, ## 
- p < 0.01; significant difference between indi-
cated female groups; * - p < 0.05; * * - p < 0.01 
significant difference between indicated male 
groups (Kruskal-Wallis ANOVA, followed by the 
Mann-Whitney test). Graphs show Mean±SD. 
Scale-bar = 20 µm.   
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can ultimately lead to apoptosis and cell death (Ozcan et al., 2004; Liu 
et al., 2020). Furthermore, ER stress can trigger mechanisms of non-
apoptotic cell death characterized by autophagy (Kawakami et al., 
2009). A number of studies proved restoring effects of liraglutide and of 
other GLP-1 analogs on the ER stress in different tissues and models 
(Panagaki et al., 2017; Sharma et al., 2011; Bretón-Romero et al., 2018; 
Liu et al., 2020; Ren et al., 2020; Fu et al., 2020). By restoring the 
damaged ER function, liraglutide treatment could increase the rate of 
protection and proper folding of connexins, with a lower rate of 
improperly folded connexins predicted for autophagic degradation. 
Metformin could also have similar role which leads to upregulation of 
Cx45 as it was found to decrease ER stress and inhibits autophagy 
pathways in peripheral blood mononuclear cells of patients with type 2 
diabetes (Diaz-Morales et al., 2018). In support to the above mentioned, 
Kawakami et al. demonstrated that ER stress induces autophagy in 
proximal tubular cells (Kawakami et al., 2009), where we observed Cx45 
upregulation when each drug was used, indicating that they might 
reduce a rate of ER stress and connexin autophagy. 
The role of Panx1 in the kidneys is still not completely clear. It is 
involved in pathophysiology of insulin resistance and regulation of 
blood pressure (Chiu et al., 2018). In our previous study, we reported 
significant upregulation of Panx1 in the kidneys of rats with DM1 (Luetić 
et al., 2020) implicating its possible role in various mechanisms asso-
ciated with DM such as inflammation, endothelial dysfunction and 
fibrosis (Singh and Kari, 2013). Pro-inflammatory effects of Panx1 are 
well known (Poudel and Okusa, 2019) and recently some studies 
observed its pro-fibrotic effects as well (Cogliati et al., 2016a). In the 
present study, we demonstrated a significant increase of tubular Panx1 
expression in metformin-treated female rats which could be connected 
to the observed tubulointerstitial fibrosis that was the most prominent in 
the same group of animals. Although there is still no data which support 
the involvement of Panx1 in renal fibrosis, a few studies proved the 
association of Panx1 with the development of fibrosis in the myocar-
dium (Dolmatova et al., 2012; Cogliati et al., 2016a). Panx1 is a possible 
marker of early renal damage and could be a therapeutic target for 
attenuation of acute kidney damage (Poudel and Okusa, 2019). Inhibi-
tion of Panx1 channels in mice is beneficial in experimental acute kidney 
injury (Poudel and Okusa, 2019). In glomeruli, however, we demon-
strated upregulation of Panx1 in the group of male rats on metformin 
therapy. As mentioned before, metformin-treated male rats had the 
thickest BC so we can speculate that there is a positive correlation be-
tween the process of membrane thickening and expression of Panx1 in 
renal tissue. In support of this idea, is the finding that Panx1 channels 
activate fibroblasts in cardiac injury which then produce extracellular 
matrix (ECM) proteins and collagen leading to fibrosis (Dolmatova et al., 
2012). This mechanism could also be responsible for activation of 
glomerular parietal epithelial cells and their production of ECM proteins 
and collagen secretion, causing thickening of BC. 
We demonstrated considerable differences between male and female 
animals regarding the therapy they received. The sex-specific effect of 
metformin was observed previously in a study in which metformin 
reversed and prevented neuropathic pain in only male mice (Inyang 
et al., 2019). Sex dependent effect of metformin could be explained by 
female hormones, primarily estrogen. Estrogen is involved in many 
physiological functions including growth, cell differentiation and regu-
lation of ECM protein production (Soldano et al., 2010; Park et al., 
2017). Some of these processes are involved in the BC thickening 
(Holderied, 2015). Metformin has a significant role in inhibiting mRNA 
and protein expression of estrogen regulated genes so the production of 
ECM proteins is blocked (Park et al., 2017). This inhibition is probably 
more intensified in females due to the higher estrogen levels. This could 
explain why male animals had the thickest BC. Nevertheless, previous 
studies found lower urinary excretion of metformin in female in com-
parison to male rats, which was caused by different expression levels of 
organic cation transporter 2 (OCT2) in proximal tubules (Ma et al., 
2016; Gai et al., 2016). and accumulation of metformin in the kidneys 
(Ma et al., 2016). Since the expression of OCT2 is considerably increased 
in HFD-induced obese mice (Gai et al., 2016), so HFHSD has additional 
effects on gender-related kidney injury in metformin-treated male rats 
with MS. The main shortage of this study is that, as many of the similar 
studies, we used only immunohistochemistry for analysis of connexin 
and pannexin expression (Kanczuga-Koda et al., 2004, 2006; Camelliti 
et al., 2004; Torres et al., 2005; Takenaka et al., 2008; Paštar et al., 2021; 
Lozić et al., 2021; Jurić et al., 2020; Kosović et al., 2020a, 2020b; Luetić 
et al., 2020). However, results of the western blot analysis would give us 
an information only about the amount of certain protein in tissue, but 
not on the distribution of the certain protein in cells or in tissue (Cogliati 
et al., 2016b). 
In conclusion, we demonstrated for the first time that HFHSD causes 
thickening of the BC in glomeruli. Both of the treatments failed to 
ameliorate the observed BC thickening caused by the HFHSD treatment. 
Moreover, using metformin even worsened it. We found that the effects 
of metformin and liraglutide in kidneys of HFHSD-fed rats are mostly 
sex-dependent. Besides the differences in the tubulointerstitial fibrosis 
score and the thickness of the BC, sex-dependent effects also included 
changes in renal Cx45 and Panx 1 expression that had not been previ-
ously studied. Both drugs changed the Cx45 and Panx 1 expression, 
pointing out that their effects on the kidney could be related to 
amelioration of disruptions in gap junction-mediated intercellular 
communication. On the other hand, we found a tremendous increase in 
cellular mitochondria in the proximal tubuli of both metformin- and 
liraglutide-treated HFHSD-fed rats, but these effects were not dependent 
on the sex of the animals. 
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